Neoadjuvant Rapid Evaluation

Collects tumor biopsies and conducts biomarker and molecular testing to assess treatment response in the I-SPY 2 Trial and related studies.

Runs the I-SPY 2 COVID/ARDS program to identify therapies that reduce mortality and mechanical ventilation duration in Acute Respiratory Distress Syndrome (ARDS) patients, expanding the I-SPY platform beyond oncology.

Operates I-SPY Phase 1b, an open-label platform study evaluating single agents or combinations in the treatment of metastatic breast cancer.

Runs the I-SPY 2 COVID/ARDS expansion trial to identify treatments that reduce mortality and mechanical ventilation duration in patients with Acute Respiratory Distress Syndrome, including those affected by COVID-19.

Expands the I-SPY platform to conduct Phase 1b trials for metastatic breast cancer and the I-SPY 2 COVID/ARDS trial to identify therapies that reduce mortality and mechanical ventilation duration in ARDS patients.

Runs the Phase 2 RECAST DCIS platform trial across 40 U.S. sites to evaluate investigational endocrine therapies and active surveillance as alternatives to surgery for Ductal Carcinoma In Situ (DCIS), aiming to prevent progression to invasive breast cancer.

Runs the Phase 2 RECAST DCIS platform trial to evaluate alternative treatments for ductal carcinoma in situ (DCIS), including active surveillance and investigational endocrine therapies, with the goal of reducing unnecessary surgery; enrolling over 300 patients across 40 U.S. sites in collaboration with pharmaceutical partners.

Leads the I-SPY 2 Trial, an adaptive platform trial for neoadjuvant treatment of locally advanced breast cancer, conducted at approximately 50 clinical sites nationwide to evaluate drug efficacy and safety while reducing trial duration and participant numbers.

Leads the I-SPY 2 Trial, an adaptive platform trial for neoadjuvant treatment of locally advanced breast cancer, conducted across approximately 50 U.S. clinical sites to evaluate drug efficacy and safety while reducing trial duration and participant numbers.

Conducts the RECAST DCIS Phase 2 platform trial to evaluate noninvasive treatment approaches and active surveillance for Ductal Carcinoma In Situ (DCIS), aiming to reduce unnecessary surgery; enrolls over 300 patients across 40 U.S. sites in collaboration with pharmaceutical partners.

Provides neoadjuvant drug therapy as part of clinical trial treatment for newly diagnosed patients with locally advanced breast cancer, including participation in investigational drug trials.

Provides neoadjuvant drug therapy as part of investigational clinical trials for newly diagnosed patients with locally advanced or aggressive breast cancer, including triple-negative subtypes, resulting in documented pathologic complete responses.

Administers investigational neoadjuvant drug therapies to newly diagnosed breast cancer patients as part of clinical trial treatment protocols.

Supports patient enrollment in clinical trials resulting in documented pathologic complete responses, including cases involving triple-negative breast cancer and ER+/HER2- subtypes, with long-term follow-up and engagement strategies.

Implements the ACCESS initiative to rebuild trust and increase participation of under-represented communities in clinical trials through targeted outreach and engagement strategies.

Works to rebuild trust and improve access to clinical trials for underrepresented populations through the ACCESS initiative.

Runs the ACCESS initiative to rebuild trust and improve access to clinical trials for under-represented populations, enhancing equity in research participation.

Conducts follow-up data projects and patient engagement strategies for the I-SPY 2 Trial to support long-term research outcomes and participant retention.